Free Trial
NYSE:AMPE

Ampio Pharmaceuticals (AMPE) Stock Price, News & Analysis

Ampio Pharmaceuticals logo
$0.0027 -0.13 (-97.93%)
As of 06/11/2025 01:54 PM Eastern

About Ampio Pharmaceuticals Stock (NYSE:AMPE)

Key Stats

Today's Range
$0.0027
$0.0027
50-Day Range
$0.00
$0.13
52-Week Range
$0.00
$0.45
Volume
140 shs
Average Volume
459 shs
Market Capitalization
$3.06 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

Ampio Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
6th Percentile Overall Score

AMPE MarketRank™: 

Ampio Pharmaceuticals scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Ampio Pharmaceuticals.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Ampio Pharmaceuticals is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Ampio Pharmaceuticals is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Ampio Pharmaceuticals has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.01% of the float of Ampio Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Ampio Pharmaceuticals has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • Dividend Yield

    Ampio Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Ampio Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.01% of the float of Ampio Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Ampio Pharmaceuticals has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • Search Interest

    2 people have searched for AMPE on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Ampio Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Ampio Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.30% of the stock of Ampio Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 5.73% of the stock of Ampio Pharmaceuticals is held by institutions.

  • Read more about Ampio Pharmaceuticals' insider trading history.
Receive AMPE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ampio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMPE Stock News Headlines

2025 Market Crash
50-Year Legend: Here's The Day Stocks Likely Crash Investing legend finds best cycle indicator during 50-year career, uses it to call crashes of 2018 and 2022 – now predicts exact day next crash starts.
Ampio Pharmaceuticals, Inc. (AMPE)
Ampio Pharmaceuticals Inc
See More Headlines

AMPE Stock Analysis - Frequently Asked Questions

Ampio Pharmaceuticals' stock was trading at $0.0026 on January 1st, 2025. Since then, AMPE stock has increased by 3.8% and is now trading at $0.0027.
View the best growth stocks for 2025 here
.

Ampio Pharmaceuticals, Inc. (NYSE:AMPE) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.40) EPS for the quarter, meeting the consensus estimate of ($0.40).

Ampio Pharmaceuticals's stock reverse split on Tuesday, September 12th 2023. The 1-20 reverse split was announced on Thursday, August 31st 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of AMPE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ampio Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Trevena (TRVN), GE Aerospace (GE) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

Last Earnings
11/10/2021
Today
6/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:AMPE
Employees
20
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$4.04 per share
Price / Book
0.00

Miscellaneous

Free Float
1,098,000
Market Cap
$3.06 thousand
Optionable
No Data
Beta
4.92
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NYSE:AMPE) was last updated on 6/12/2025 by MarketBeat.com Staff
From Our Partners